ReviewNature reviews. Cardiology2020
Diagnostic imaging of cardiac amyloidosis.
Review in Nature reviews. Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05442203 (Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease), which is not on this map. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it, 174 citations in OpenAlex.
- Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: a meta-analysis.BMC cardiovascular disorders · 2021Pooled it
- Apolipoprotein A-IV Cardiac Amyloidosis Presenting as Massive Ventricular Wall Thickening Mimicking Hypertrophic Cardiomyopathy.JACC. Case reports · 2026Article
- Imaging Advances in Light Chain Amyloidosis.Diagnostics (Basel, Switzerland) · 2026Review
- Expert Consensus and Clinical Pathway Recommendations for Transthyretin Amyloid Cardiomyopathy in Malaysia.International journal of heart failure · 2026Review
- AI-assisted diagnosis of cardiac amyloidosis using electrocardiograms and echocardiography: a multicenter retrospective study in China.BMC medicine · 2026Article
- Unexplained heart failure with preserved ejection fraction diagnosed as amyloidosis of the heart.Journal of geriatric cardiology : JGC · 2026Article
- Diagnostic Value of Native T1 and T2 Mapping in Differentiating Clinically Suspected Amyloidosis and Hypertrophic Cardiomyopathy.Diagnostics (Basel, Switzerland) · 2026Article
- Development and Internal validation of a simple echocardiography score for diagnosis of cardiac amyloidosis.Journal of thoracic disease · 2026Article
- Significance of regional myocardialThe international journal of cardiovascular imaging · 2026Article
- [Genes & diseases · 2026Article
- Concomitant Cardiac Transthyretin Amyloidosis and Coronary Artery Disease---Imaging Features and Pitfalls.CJC open · 2026Review
- Novel Cut-Off Values of Precordial Voltage Indexes for Light Chain Amyloidosis Cardiomyopathy in a Chinese Population.Journal of cardiovascular development and disease · 2026Article
- Case Report: Hereditary ATTR-CA presenting with recurrent severe abdominal cramps: a diagnostic challenge.Frontiers in cardiovascular medicine · 2026Article
- The Thickness That Deceives: The Role of Imaging, Biopsy, and Genetics in the Evaluation of Ventricular Hypertrophy.Arquivos brasileiros de cardiologia · 2026Article
- Concurrent light chain and transthyretin cardiac amyloidosis: A case report and review of the literature.Medicine · 2025Review
- Development of an artificial intelligence-based early diagnostic system for light-chain amyloidosis.Annals of hematology · 2025Article
- Differentiation of light chain cardiac amyloidosis and hypertrophic cardiomyopathy by ensemble machine learning-based radiomic analysis of cardiac magnetic resonance.Orphanet journal of rare diseases · 2025Article
- Predicting prognosis of light-chain cardiac amyloidosis by magnetic resonance imaging and deep learning.European heart journal. Cardiovascular Imaging · 2025Article
- Skin Biopsy as a Diagnostic Tool for ATTRv Amyloid Neuropathy in the UK.Journal of the peripheral nervous system : JPNS · 2025Article
- Hypertrophic cardiomyopathy unveiling multiple myeloma: A diagnostic challenge.Radiology case reports · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Systemic amyloidosis encompasses a debilitating, under-diagnosed but increasingly recognized group of disorders characterized by the extracellular deposition of misfolded proteins in one or more organs. Cardiac amyloid deposition leads to an infiltrative or restrictive cardiomyopathy and is the major contributor to poor prognosis in patients with systemic amyloidosis. In total, >30 proteins can form amyloid fibrils, but the two main types of amyloid that can infiltrate the heart are monoclonal immunoglobulin light-chain amyloid and transthyretin amyloid. Cardiac amyloidosis can be acquired in older individuals or inherited from birth. Given the nonspecific symptoms of these disorders, a high index of suspicion is paramount in making the correct diagnosis, which can involve the use of non-invasive imaging methods such as echocardiography, bone scintigraphy and cardiovascular MRI. In the past decade, the use of cardiovascular MRI with tissue characterization and bone scintigraphy to diagnose cardiac amyloidosis has revolutionized our understanding of the disease, leading to changes in patient care. However, a need remains for improved awareness and expertise, and greater clinical suspicion, because the initial clues provided by electrocardiography and echocardiography might not be typical. With specific treatments now available, timely diagnosis of cardiac amyloidosis is more important than ever. In this Review, we discuss the current and novel approaches for the diagnostic imaging of cardiac amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.